All In Biotech

Drug Trial Radar · NCT02585934

Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study

A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Dec 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,315 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,315

Actual

Start

Oct 2015

Primary completion

Sep 2017

Study completion Sep 2017

Sponsor

Lead sponsor
Axovant Sciences Ltd.Industry
Sponsor type
Industry
First posted
Oct 26, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study seeks to confirm a demonstrated treatment effect of intepirdine (RVT-101) as an adjunctive therapy to donepezil for the treatment of subjects with Alzheimer's disease.

Conditions

  • Alzheimer's Disease

Interventions

  • RVT-101Drug

    once daily, oral, 35 mg tablets

  • PlaceboDrug

    once daily, oral, pill manufactured to match RVT-101 35 mg tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Alzheimer's Disease Assessment Scale - Cognitive Subscale 11 Items (ADAS-Cog-11) Score Change From Baseline to Week 24Time frame: Baseline, 24 weeks
  2. Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score Change From Baseline to Week 24Time frame: Baseline, 24 weeks

Locations

197 sites in 19 countries. Site status is shown where the registry gives one.

  • US112

    Phoenix, Arizona

  • US220

    Tucson, Arizona

  • US168

    Encino, California

  • US117

    Fullerton, California

  • US214

    Los Angeles, California

  • US189

    Pasadena, California

  • US096

    Rancho Mirage, California

  • US0195

    Santa Ana, California

  • US016

    Simi Valley, California

  • US106

    Temecula, California

  • US179

    Hamden, Connecticut

  • US171

    Norwich, Connecticut

  • US088

    Atlantis, Florida

  • US007

    Brooksville, Florida

  • US002

    Hallandale, Florida

  • US140

    Hialeah, Florida

  • US216

    Miami, Florida

  • US110

    Miami, Florida

  • US172

    North Palm Beach, Florida

  • US003

    Orlando, Florida

  • US256

    Pensacola, Florida

  • US037

    Tampa, Florida

  • US042

    Tampa, Florida

  • US004

    The Villages, Florida

  • US048

    Atlanta, Georgia

  • US046

    Atlanta, Georgia

  • US217

    Columbus, Georgia

  • US111

    Baton Rouge, Louisiana

  • US095

    Shreveport, Louisiana

  • US116

    Newton, Massachusetts

  • US174

    Quincy, Massachusetts

  • US144

    Hattiesburg, Mississippi

  • US094

    Las Vegas, Nevada

  • US135

    Berlin, New Jersey

  • US197

    Lawrenceville, New Jersey

  • US215

    Mount Arlington, New Jersey

  • US057

    Paterson, New Jersey

  • US209

    Toms River, New Jersey

  • US036

    West Long Branch, New Jersey

  • US001

    Albany, New York

Showing 40 of 197 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.